Rinvoq Receives FDA Approval for Updated IBD Indications
The Food and Drug Administration (FDA) has approved updated indications for Rinvoq® (upadacitinib) in the treatment of adults with moderately to severely active ulcerative colitis (UC) or Crohn disease (CD).
Prior to this approval, Rinvoq had been indicated for adults with moderately to severely active UC or CD who had an inadequate response or intolerance to 1 or more tumor necrosis factor (TNF) blockers.
The updated indications now state that if TNF blockers are clinically inadvisable, patients may still be administered Rinvoq if they have previously received at least 1 approved systemic therapy.
Author's summary: Rinvoq gets FDA approval update.
More News
- 3 Editors Are Running The NYC Marathon. They Say They Wouldn't Have Made It Through Training Without These Products.
- Report: Ireland Stalwart Considering Shock Move To Breakway League | Balls.ie
- Air Ambulance fight is over as Welshpool loses base
- Nottingham Forest v Chelsea on TV today – Watch live - TVWise.co.uk
- Washington's neglect of South Korea’s security concerns is a proliferation problem
- It's official - Pennsylvania, New Jersey and Delaware among states that must switch to daylight saving time - these are the ones that must not
- Solo Leveling x Frieren Crossover Announced: The Anime Event Fans Wanted | TechLatest
- The 5 Biggest State Tax Cuts for Millionaires this Year
- Platforms of Extremism: Why Australia Must Confront Digital Misogyny as a Security Threat - Australian Institute of International Affairs
- Dean Huijsen is working hard to be fit to face Juventus